Impact of socioeconomic determinants of health on delays to care in gastric cancer: A national cancer database analysis.
1/5 보강
[INTRODUCTION] The impact of demographic and socioeconomic backgrounds on delays to cancer care and subsequent mortality for those with resectable gastric adenocarcinoma is not well studied.
- p-value p < 0.001
- p-value p = 0.038
APA
Yee EJ, Stuart CM, et al. (2025). Impact of socioeconomic determinants of health on delays to care in gastric cancer: A national cancer database analysis.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 51(9), 110136. https://doi.org/10.1016/j.ejso.2025.110136
MLA
Yee EJ, et al.. "Impact of socioeconomic determinants of health on delays to care in gastric cancer: A national cancer database analysis.." European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, vol. 51, no. 9, 2025, pp. 110136.
PMID
40398013 ↗
Abstract 한글 요약
[INTRODUCTION] The impact of demographic and socioeconomic backgrounds on delays to cancer care and subsequent mortality for those with resectable gastric adenocarcinoma is not well studied. We sought to investigate the relationship between sociodemographic determinants of health, delays to consensus guideline therapy, and survival outcomes for gastric cancer.
[METHODS] Patients with gastric cancer from the National Cancer Database (2004-2020) were partitioned into early-stage (AJCC Stage 0-I) and locoregionally advanced (Stage II-resectable stage IV) disease receiving upfront surgery and neoadjuvant therapy (NAT) followed by surgical resection, respectively. The primary outcome was odds of delay to upfront surgery or NAT initiation/post-NAT resection. Secondary outcomes were short-term (30-, 90-day) mortality and long-term survival.
[RESULTS] A total of 18,307 patients were identified; 10,623 and 7684 patients had early-stage and locoregionally advanced disease, respectively. The median [interquartile range] time to upfront surgery: 42 [22-66] days, NAT initiation: 40 [29-54] days, and post-NAT resection: 55 [44-69] days from end of NAT. In adjusted analysis, African American race, Medicaid or non-Medicare governmental insurance coverage, and lower educational and/or income status were significantly associated with delayed initiation of preoperative therapies. Delayed upfront surgery was associated with worse long-term survival (HR 1.15 [1.05-1.23], p < 0.001); delayed post-NAT surgery but not delayed NAT initiation portended worse 90-day mortality (HR 1.31 [1.02-1.69], p = 0.038) and long-term survival (HR 1.21 [1.10-1.32], p < 0.001).
[CONCLUSION] Demographic and socioeconomic characteristics are associated with delays in receiving consensus guideline therapy for gastric cancer and translate to significantly worse survival outcomes.
[METHODS] Patients with gastric cancer from the National Cancer Database (2004-2020) were partitioned into early-stage (AJCC Stage 0-I) and locoregionally advanced (Stage II-resectable stage IV) disease receiving upfront surgery and neoadjuvant therapy (NAT) followed by surgical resection, respectively. The primary outcome was odds of delay to upfront surgery or NAT initiation/post-NAT resection. Secondary outcomes were short-term (30-, 90-day) mortality and long-term survival.
[RESULTS] A total of 18,307 patients were identified; 10,623 and 7684 patients had early-stage and locoregionally advanced disease, respectively. The median [interquartile range] time to upfront surgery: 42 [22-66] days, NAT initiation: 40 [29-54] days, and post-NAT resection: 55 [44-69] days from end of NAT. In adjusted analysis, African American race, Medicaid or non-Medicare governmental insurance coverage, and lower educational and/or income status were significantly associated with delayed initiation of preoperative therapies. Delayed upfront surgery was associated with worse long-term survival (HR 1.15 [1.05-1.23], p < 0.001); delayed post-NAT surgery but not delayed NAT initiation portended worse 90-day mortality (HR 1.31 [1.02-1.69], p = 0.038) and long-term survival (HR 1.21 [1.10-1.32], p < 0.001).
[CONCLUSION] Demographic and socioeconomic characteristics are associated with delays in receiving consensus guideline therapy for gastric cancer and translate to significantly worse survival outcomes.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (3)
- From Early Detection To Advanced Therapies: How Circulating Tumor DNA Is Transforming the Care of Colorectal Cancer.
- Dynamic Anthropometrics in Pancreatic Cancer: Associations Between Body Composition Changes During Neoadjuvant Therapy and Survival Outcomes After Resection.
- Radiologic Occult Metastases in Pancreatic Cancer: Analysis of Risk Factors and Survival Outcomes in the Age of Contemporary Neoadjuvant Multi-agent Chemotherapy.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.